This record was last updated January 22, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.